Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025

Globe and Mail

5 days ago

New York, New York--(Newsfile Corp. - August 6, 2025) - If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=160082&wire=5&utm_campaign=28
or contact Joseph E. Levi, Esq. via email at [e-mail] or call [phone] to speak to our team of experienced shareholder advocates.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=bar7Q9XIFkc
THE LAWSUIT: A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between September 17, 2024 and May 26, 2025.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices.
On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred.
Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.
WHAT'S NEXT? If you suffered a loss in Rocket stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=160082&wire=5&utm_campaign=28 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261562